Valuation: GENFIT

Market Cap 465M 524M 436M 395M 744M 50.49B 750M 5.23B 2.03B 25.75B 1.97B 1.92B 82.85B P/E 2026 *
84.8x
P/E 2027 * 98.7x
Enterprise Value 444M 500M 416M 376M 710M 48.15B 716M 4.99B 1.94B 24.56B 1.88B 1.83B 79.02B EV / Sales 2026 *
4.09x
EV / Sales 2027 * 3.06x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-3.26%
3 months+46.51%
6 months+51.01%
Current year+162.50%
Current year 7.26
Extreme 7.26
16.5
1 year 4.14
Extreme 4.14
16.5
3 years 2.95
Extreme 2.95
16.5
5 years 2.95
Extreme 2.95
16.5
10 years 0
Extreme 0
36.86
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%-.--% - - 518M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-0.93%+327.90%+691.25% 44.51B
-2.30%-4.06%+25.82%+31.42% 43.8B
+0.31%-1.15%+5.50%+112.56% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-3.38%-9.25%-12.85% 24.53B
Average +0.06%-0.20%+52.55%+125.61% 43.73B
Weighted average by Cap. +0.76%-0.50%+56.58%+134.21%

Financials

2026 *2027 *
Net sales 109M 122M 102M 92.04M 174M 11.77B 175M 1.22B 474M 6.01B 458M 449M 19.32B 130M 146M 122M 110M 208M 14.09B 209M 1.46B 568M 7.19B 549M 537M 23.13B
Net income 10.3M 11.6M 9.65M 8.74M 16.48M 1.12B 16.61M 116M 45.03M 570M 43.52M 42.59M 1.83B 10.37M 11.67M 9.71M 8.79M 16.58M 1.12B 16.72M 117M 45.32M 574M 43.8M 42.86M 1.85B
Net Debt -21.52M -24.23M -20.15M -18.25M -34.42M -2.34B -34.7M -242M -94.08M -1.19B -90.92M -88.98M -3.83B -67.56M -76.07M -63.27M -57.3M -108M -7.33B -109M -759M -295M -3.74B -285M -279M -12.03B
Projected Income Statement - Annual - GENFIT
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - GENFIT
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.300EUR
Average target price
17.48EUR
Spread / Average Target
+87.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GENFIT